|
|
(62 intermediate revisions by 5 users not shown) |
Line 17: |
Line 17: |
| :follow the instructions for subscribing | | :follow the instructions for subscribing |
|
| |
|
| *We meet in the Knight Conference Room 14th floor Hatfield Research Bldg | | *We meet in Mac Hall 2201 |
| :Fridays 9:15-10:15 AM - see schedule below | | :Fridays 9:00-10:15 AM - see schedule below |
| :Breakfast provided by the Knight! | | :Breakfast provided by the Knight! |
| *Organizer: Rosie Sears, email searsrATohsu.edu | | *Organizer: Rosie Sears, email searsrATohsu.edu |
|
| |
|
| ==Member Labs and Affiliations==
| |
|
| |
|
| [http://www.ohsu.edu/ohsuedu/healthcare/hemonc/faculty/lopez.cfm Lopez Lab] Hem Onc
| |
|
| |
| [http://openwetware.org/wiki/Sears Sears Lab], MMG
| |
|
| |
| [http://openwetware.org/wiki/Hoatlin_Lab Hoatlin Lab], BMB
| |
|
| |
| [http://openwetware.org/wiki/Thayer_Lab Thayer Lab], BMB
| |
|
| |
| [http://www.ohsu.edu/croet/faculty/lloyd/ Lloyd Lab], CROET
| |
|
| |
| [http://www.ohsu.edu/croet/faculty/mccullough/ McCullough Lab], CROET
| |
|
| |
| [http://openwetware.org/wiki/Wong_Lab Wong Lab], Dermatology, CDB
| |
|
| |
| [https://www.openwetware.org/wiki/Zundel Zundel Lab], Radiation Medicine, Cancer Biology
| |
|
| |
| [http://www.ohsu.edu/academic/som/ngp/faculty-profile.cfm?facultyID=346 Spindel Lab], Primate Center, NGP, Cancer Biology
| |
|
| |
| *Add your lab here
| |
|
| |
|
| ==Schedule== | | ==Schedule== |
| <font color=red>*Red indicates Translational Cancer Research Group Meetings</font>
| |
|
| |
| <div style="padding: 10px; width: 800px; border: 5px solid #B3CD4E;">
| |
|
| |
| {| border="1" cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse; width:800px" <!-- This line here formats your table for you. Change the code to change the formatting of your table.-->
| |
| | align="center" style="background:#f0f0f0;"|'''Date'''
| |
| | align="center" style="background:#f0f0f0;"|'''Presenters'''
| |
| | align="center" style="background:#f0f0f0;"|'''Topic'''
| |
| | align="center" style="background:#f0f0f0;"|'''Links & Comments'''
| |
| | align="center" style="background:#f0f0f0;"|'''Location'''
| |
|
| |
| |--
| |
| | 9/21/2012
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| | <font color=red>9/28/2012</font>
| |
| |
| |
| |Hematologic Malignancies -
| |
| |
| |
| |
| |
| |--
| |
| |10/5/2012
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| | <font color=red>10/12/2012</font>
| |
| |
| |
| |Hematologic Malignancies -
| |
| |
| |
| |
| |
| |--
| |
| |10/19/2012
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| | <font color=red>10/26/2012</font>
| |
| |
| |
| |Hematologic Malignancies -
| |
| |
| |
| |
| |
| |--
| |
| |11/2/2012
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| | <font color=red>11/9/2012</font>
| |
| |
| |
| |Hematologic Malignancies -
| |
| |
| |
| |
| |
| |--
| |
| | 11/16/2012
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| |<font color=red>11/30/2012</font>
| |
| |
| |
| |Hematologic Malignancies -
| |
| |
| |
| |
| |
| |--
| |
| |12/7/2012
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| |<font color=red>12/14/2012</font>
| |
| |
| |
| |Hematologic Malignancies - Brain storming
| |
| |
| |
| |
| |
| |--
| |
| |12/21/2012
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| | <font color=red>1/4/2013</font>
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| |1/11/2013
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| | <font color=red>1/18/2013</font>
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| |1/25/2013
| |
| |
| |
| |
| |
| |
| |
| |--
| |
| | <font color=red>2/17/2012</font>
| |
| |
| |
| Lisa Coussens
| |
|
| |
| | Breast Cancer:Inflammation and Breast Cancer: Targeting Macrophages to Enhance Chemotherapy
| |
| |
| |
| |
| |
| |--
| |
| |2/24/2012
| |
| |George Thomas
| |
| |Re-thinking Targeted Therapies for Kidney Cancer
| |
| |
| |
| |
| |
| |--
| |
| | <font color=red>3/2/2012</font>
| |
| |Juha Rantala
| |
| Koei Chin
| |
| |Breast Cancer (Rantala): Targeted RNAi screens in breast cancer cells using cell spot microarrays.
| |
|
| |
| Breast Cancer (Chin): Omics Analysis in Breast Cancer: Genome to Protein
| |
| |
| |
| |
| |
| |--
| |
| |3/9/2012
| |
| |Daniel Marks
| |
| |Brain Mechanisms in Cancer Cachexia
| |
| |
| |
| |
| |
| |--
| |
| | <font color=red>3/16/2012</font>
| |
| |Xiangshu Xiao
| |
| |Breast Cancer: Small Molecules Targeting CREB for Breast Cancer Therapy
| |
| |
| |
| |
| |
| |--
| |
| |3/23/2012
| |
| |Canceled for the 2012 BioMedicine in 4D Conference
| |
| |[http://www.ohsu.edu/xd/education/schools/school-of-medicine/departments/basic-science-departments/biomedical-engineering/spatial-systems-biomedicine/conference.cfm]
| |
| |
| |
| |
| |
| |--
| |
| | 3/30/2012
| |
| |NO MEETING
| |
| | Spring Break
| |
| |
| |
| |
| |
| |--
| |
| |<font color=red>4/6/2012</font>
| |
| | Allen Ebens, PhD
| |
| | The role of PI3 and PIM kinases in multiple myeloma
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |
| |--
| |
| |4/13/2012
| |
| |Jen Vomaske
| |
| |CXCR7-mediated Endothelial Dysfunction: Implications for Tumor Vascular Normalization
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |
| |--
| |
| | <font color=red>4/20/2012</font>
| |
| | Zhi Hu
| |
|
| |
| Wassana Yantasee
| |
|
| |
| | Part I. Optimization of therapeutic siRNA against HER2 (Hu)
| |
|
| |
| Part II. Nanoparticle platform for siRNA delivery and HER2 silencing (Yantasee)
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |
| |--
| |
| |4/27/2012
| |
| |Lucia Carbone
| |
| |Mechanisms of chromosomal rearrangement in evolution and cancer
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |
| |--
| |
| | <font color=red>5/4/2012</font>
| |
| |Joe Gray
| |
|
| |
| Paul Spellman
| |
| |Breast Cancer: Prospects for interrogating the signaling nanostructure of breast cancer
| |
|
| |
| Breast Cancer:Genomic Analysis of Breast Cancers. Beyond TCGA
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |
| |--
| |
| |5/11/2012
| |
| |Wong Lab (Nick Smith, Emily Bubbers)
| |
| |
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |
| |--
| |
| | <font color=red>5/18/2012</font>
| |
| | John Muschler
| |
|
| |
| Sunjong Kwon
| |
|
| |
|
| |Breast Cancer
| | == <font color=red>Please click here for the full Knight Cancer Biology and Translational Research Group Meeting schedule: https://bridge.ohsu.edu/research/knight/groups/KnightResearchGroups/SitePages/CancerBiologyandTranslational.aspx</font> == |
| Sunjong Kwon: Quantitative Imaging of individual mRNAs and co-staining of protein in breast cancer cells
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |
| |--
| |
| | <font color=red>5/25/2012</font>
| |
| |Brainstorming - Breast Cancer Focus
| |
| |
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |
| |--
| |
| |6/8/2012
| |
| |Kinrin Yamanaka (Dr. Stephen Lloyd lab)
| |
| |Molecular Targeting of Translesion Synthesis DNA Polymerases for Novel Combination Chemotherapy
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |
| |--
| |
| |6/15/2012
| |
| |Liskay Lab
| |
| |Inhibiting occult clonal expansion of mutant cells as a mechanism of chemoprevention
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |
| |--
| |
| |6/22/2012
| |
| |Neil Osheroff
| |
| |Vanderbilt
| |
| |<font color=green> ***Note the location change ***
| |
| |MAC HALL 2201
| |